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BACKGROUND: Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification 
of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus 
risk from this strategy.
METHODS AND RESULTS: PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54) randomized 21 162 patients with 
prior myocardial infarction in a 1:1:1 fashion to ticagrelor 60 mg or 90 mg twice daily or placebo, with ticagrelor 60 mg approved for 
long-term use. TIMI major or minor bleeding was the primary end point for this analysis. Causes of bleeding were categorized by 
site and etiology, and independent predictors were identified. At 3 years, ticagrelor 60 mg increased the rate of TIMI major or minor 
bleeding by 2.0% versus placebo (1.4% placebo versus 3.4% ticagrelor). The bleeding excess was driven primarily by spontaneous 
gastrointestinal bleeds. A history of spontaneous bleeding requiring hospitalization and the presence of anemia were independent 
predictors of bleeding but not of ischemic risk. Patients with at least 1 risk predictor had 3-fold higher rates of bleeding with ticagre-
lor 60 mg versus those who had neither (absolute risk increase, 4.4% versus 1.5%; P=0.01). Patients with neither predictor had a 
more favorable benefit profile with ticagrelor 60 mg versus placebo including lower mortality (hazard ratio, 0.79; 95% CI, 0.65–0.96; 
P interaction = 0.03).
CONCLUSIONS: In patients with prior myocardial infarction, bleeding with ticagrelor 60 mg twice daily is predominantly spontaneous 
gastrointestinal. A history of spontaneous bleeding requiring hospitalization or the presence of anemia identifies patients at higher 
risk of bleeding, and the absence of either identifies patients likely to have a more favorable net benefit with ticagrelor.
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L
ong-term therapy with ticagrelor 60 mg twice daily 
added to aspirin in patients with a previous myo-
cardial infarction (MI) reduced major adverse car-
diovascular events in the PEGASUS-TIMI 54 (Prevention 
of Cardiovascular Events in Patients With Prior Heart 
Attack Using Ticagrelor Compared to Placebo on a 
Background of Aspirin—Thrombolysis in Myocardial 
Infarction 54) trial.1 Based on this finding, ticagrelor 
60 mg twice daily has been approved in Europe and 
the United States for long-term use for secondary pre-
vention after MI.2 However, ticagrelor also increased the 
risk of TIMI major and minor bleeding, although it did not 
increase intracranial hemorrhage (ICH) or fatal bleeding.
Serious bleeding is an important outcome and has 
been associated with several adverse events includ-
ing hospitalizations, procedures, cessation of medi-
cations, and mortality.3 Therefore, understanding the 
sites, etiologies, and outcomes after bleeding may be 
helpful in weighing the benefits and risks of antithrom-
botic therapies. In addition, identifying patients at 
greater risk of bleeding may enable personalization of 
therapy to those at lower bleeding risk who are more 
likely to derive greater benefit. A challenge to bleeding 
risk prediction, however, is that several characteristics 
are associated with both bleeding and ischemic risk.
In this context, a post hoc analysis of bleeding in 
PEGASUS-TIMI 54 was performed, including charac-
terization of the sites and causes of bleeding. In addi-
tion, baseline characteristics independently associated 
with bleeding risk, but not ischemic risk, were identi-
fied. Finally, a post hoc analysis evaluating the efficacy 
and safety of long-term ticagrelor stratified by baseline 
bleeding risk was performed.
METHODS
Study Population
The data for the analyses are held at the TIMI Study 
Group, and the senior author may be contacted for re-
quests with regard to the sharing of data, methods, and 
materials specific to this analysis. The study protocol was 
approved by the relevant ethics committee at each partic-
ipating site. Written informed consent was obtained from 
all the patients. The PEGASUS-TIMI 54 trial, described 
previously,1,4 randomized 21 162 patients with prior spon-
taneous MI occurring 1–3 years before enrollment, who 
had at least 1 additional atherothrombotic risk factor (age 
≥65 years, diabetes mellitus requiring medication, a sec-
ond prior spontaneous MI, chronic renal dysfunction, or 
multivessel coronary artery disease) to ticagrelor 60 mg 
twice daily, ticagrelor 90 mg twice daily, or placebo in a 
1:1:1 fashion, all on a background of low-dose (75 mg–
150 mg) aspirin. The 60-mg dose was approved for long-
term secondary prevention, and therefore the primary 
group for analysis includes patients randomized to 60 mg 
(N=6958) or placebo (N=6996) with additional analyses 
for the 90-mg dose (N=6988) versus placebo included in 
the online supplement. Exclusion criteria included planned 
use of a P2Y12 receptor antagonist or anticoagulant ther-
apy, a known bleeding disorder, history of stroke, a central 
nervous system tumor, gastrointestinal bleeding within the 
previous 6 months, or major surgery within the previous 
30 days. Enrolling sites were requested to indicate if there 
CLINICAL PERSPECTIVE
What Is New?
• In stable patients with prior myocardial infarc-
tion on aspirin, TIMI (Thrombolysis in Myocardial 
Infarction) major or minor bleeding is primarily 
spontaneous of gastrointestinal origin and re-
lated to an underlying disease.
• Ticagrelor 60 mg increases spontaneous TIMI 
major or minor bleeding, including gastroin-
testinal bleeding, but does not increase fatal 
bleeding, bleeding that contributed to death, or 
spontaneous intracranial hemorrhage.
• Anemia at baseline and history of previous 
bleeding requiring hospitalization were inde-
pendent predictors of bleeding and were not 
associated with ischemic risk or the benefit of 
ticagrelor. Patients without anemia at baseline 
or history of previous bleeding requiring hospi-
talization derived greater benefit from prolonged 
ticagrelor therapy.
What Are the Clinical Implications?
• In a stable post–myocardial infarction popula-
tion, prior bleeding and anemia may be sufficient 
for bleeding risk prediction and may enable cli-
nicians to consider bleeding and ischemic risk 
independently.
• This may be particularly helpful in groups such 
as the elderly in whom assessment of risks and 
benefits may be particularly challenging.
Nonstandard Abbreviations and Acronyms
COGENT Clopidogrel and the Optimization of 
Gastrointestinal Events
ICH Intracranial hemorrhage
PEGASUS Prevention of Cardiovascular Events 
in Patients With Prior Heart Attack 
Using Ticagrelor Compared to 
Placebo on a Background of Aspirin
TIMI Thrombolysis in Myocardial Infarction
MI Myocardial infarction
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was any history of bleeding leading to hospitalization. All 
patients had central laboratory testing for hemoglobin at 
baseline. Anemia was defined as a hemoglobin ≤13.5 g/
dL for men and ≤ 12.0 g/dL for women.
End Points
The primary efficacy end point was major adverse cardio-
vascular events, consisting of the composite of cardiovas-
cular death, MI, or stroke (3-point major adverse cardiac 
event). The primary safety end point was TIMI major 
bleeding. Secondary safety end points were combined 
TIMI major and minor bleeding, as well as ICH and fatal 
bleeding. TIMI major bleeding was defined as any ICH, or 
clinically overt signs of hemorrhage associated with a re-
duction in hemoglobin ≥5 g/dL (or, when hemoglobin was 
not available, a fall in hematocrit ≥15%), or fatal bleeding 
(a bleeding event that directly led to death within 7 days). 
TIMI minor bleeding was defined as any clinically overt 
hemorrhage (including that detected by imaging) that was 
associated with a fall in hemoglobin of 3 to <5 g/dL (or, 
when hemoglobin was not available, a fall in hematocrit of 
9 to <15%). Hemoglobin measurements were adjusted for 
any packed red blood cells or whole blood given between 
baseline and posttransfusion measurement; transfusion of 
1 unit of blood was assumed to result in an increase of 
1 g/dL of hemoglobin. Bleeding events leading directly to 
mortality were classified as fatal bleeding events. Bleeding 
that was not directly fatal but was in the causal pathway 
leading to death (eg, death attributable to a nonbleeding 
complication of hospitalization prompted by bleeding) were 
classified as “bleeding contributing to death.” All bleeding 
events, as well as their relationship to mortality, were ad-
judicated by a clinical events committee blinded to treat-
ment allocation. A net clinical benefit analysis was defined 
as cardiovascular death, MI, stroke, ICH, or fatal bleeding.
Statistical Analysis
Baseline characteristics, including demographics, 
medical history, and clinical findings at randomiza-
tion were summarized using medians and quartiles 
(interquartile range) for continuous variables and fre-
quencies and percentages for categorical variables. 
Differences were tested with the Wilcoxon rank-sum 
test for continuous variables and with the Pearson χ 2 
test for categorical data. The primary efficacy analy-
sis and net clinical outcome were conducted on an 
intention-to-treat basis, whereas safety analyses in-
cluded all patients who underwent randomization and 
received at least 1 dose of study drug. Event rates 
for ticagrelor and placebo were estimated by Kaplan–
Meier methods from baseline to 3 years and compared 
with the log-rank test. In addition, the instantaneous 
hazard function for TIMI major or minor bleeding was 
also estimated by the kernel-based method.5 This was 
examined separately by treatment arm over time.
A multivariable Cox proportional hazards model was 
developed by first examining univariate associations be-
tween baseline characteristics and the risk of TIMI major 
or minor bleeding in the overall population. Clinically 
meaningful covariates that met P value thresholds of 0.1 
in univariable association were further retained for the 
pool of candidate variables. These included age, weight, 
systolic blood pressure, estimated glomerular filtration 
rate, history of spontaneous bleeding, history of diabe-
tes mellitus, history of congestive heart failure, history 
of malignancy, white blood cell count, baseline anemia, 
and smoking status. The backward elimination method 
was then used to yield the final model with the reduced 
number of risk factors based on a P value cutoff < 0.01.
Multivariable models evaluating the association be-
tween baseline characteristics and the risk of the primary 
efficacy end point were evaluated. The proportional haz-
ards assumption was examined and tested by scaled 
Schoenfeld residuals. The linearity assumption for contin-
uous variables was examined by restricted cubic spline 
plots. Characteristics that independently predicted bleed-
ing but were not independently associated with the risk 
of the primary efficacy end point were identified as those 
most useful for patient selection. The results of these 
models were described using the hazard ratio (HR) with 
the associated 95% CI. The discrimination index was 
assessed using the Harrell’s C statistic. In addition, the 
absolute risk differences between treatment and placebo 
groups were compared across high- and low-bleeding-
risk groups using the Gail–Simon 2-sided heterogene-
ity test.6 A sensitivity analysis of efficacy and safety was 
then performed, stratified by baseline bleeding risk with 
patients with a history of bleeding or anemia at baseline 
considered to be at “high bleeding risk” and those with no 
predictors of bleeding considered at “low bleeding risk.”
RESULTS
A total of 20 942 patients received at least 1 dose of the 
study drug (safety population). Baseline characteristics 
in the overall safety population, according to the oc-
currence of TIMI major or minor bleeding during follow-
up (median, 33 months), are summarized in Table 1. 
Patients who experienced a TIMI major or minor bleed 
(n=432) were older and more likely to have hyperten-
sion, renal insufficiency, a history of malignancy, a 
history of a previous spontaneous bleed requiring hos-
pitalization, and a hemoglobin value indicating anemia.
Type, Location, and Cause of Bleeding in 
All Treatment Arms
The majority of TIMI major or minor bleeding events 
were spontaneous (N=306; 71% of all bleeds) followed 
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bleeding (N=61; 14%) (Figure 1A). Spontaneous TIMI 
major or minor bleeds were primarily of gastrointes-
tinal origin (75%), followed by intracranial (12%) and 
genitourinary (6%, Figure 1B). The sites and causes of 
bleeding were similar in patients randomized to tica-
grelor 60 mg twice daily or placebo (Figure S1). Of the 
spontaneous gastrointestinal bleeds, the most com-
mon was upper gastrointestinal ulcer or inflammation 
(49%), followed by diverticular bleeding or hemor-
rhoids (20%) and previously undiagnosed neoplasm 
(17%) (Figure S2).
Treatment of and Outcomes After 
Bleeding in All Treatment Arms
Approximately half (56%) of patients who experi-
enced a spontaneous TIMI major or minor bleed 
received a transfusion or underwent a nonsurgi-
cal procedure or surgery (nonsurgical procedure, 
42%; surgery, 7%; transfusion only, 11%) to treat 
the bleeding. Of the 432 patients who experienced 
a TIMI major or minor bleed, 42 (9.7%) died of 
causes related to bleeding, with 28 having a directly 
fatal bleed and 14 in whom bleeding contributed 
to death. The median time from the bleeding event 
to death was 2.0 days (interquartile range, 0–5) for 
directly fatal bleed and 10 days (interquartile range, 
2–61) for bleeding that contributed to death. Of 
the patients who survived their bleeding, an addi-
tional 38 died later during the study (median, 207.5 
days after bleeding; interquartile range, 78–404) for 
causes unrelated to bleeding, including cardiovas-
cular causes (45%), sepsis or organ failure (18%), 
and malignancy (37%) (Figure 2).
Predictors of Bleeding in All Treatment Arms
The following variables were identified as independently 
associated with TIMI major or minor bleeding in the total 
population: age, history of hypertension, current smoking, 
history of spontaneous (nontraumatic, nonprocedural) 
Table 1. Baseline Characteristics by TIMI Major or Minor Bleeding During Follow-Up
TIMI Major or Minor 
Bleeding (N=432)
No TIMI Major or Minor 
Bleeding (N=20 510) P Value
Age, y, median (IQR) 68.0 (61.0–74.0) 65.0 (59.0–71.0) <0.0001
Female, n (%) 100/432 (23.1) 4903/20 510 (23.9) 0.71
Weight, kg, median (IQR) 79.0 (68.0–90.4) 81.0 (70.0–92.0) 0.04
History of hypertension, n (%) 359/432 (83.1) 15879/20 510 (77.4) 0.005
SBP, mm Hg, median (IQR) 132.0 (120.0–145.0) 130.0 (120.0–142.0) 0.052
History of diabetes mellitus, n (%) 139/432 (32.2) 6596/20 510 (32.2) 0.99
Current smoker, n (%) 85/432 (19.7) 3419/20 505 (16.7) 0.10
Renal dysfunction, eGFR <60 (MDRD, mL/min/1.73 m2), n (%) 130/426 (30.5) 4658/20 296 (23.0) 0.0002
History of CHF, n (%) 80/432 (18.5) 4123/20 510 (20.1) 0.42
History of malignancy, n (%) 35/432 (8.1) 1256/20 510 (6.1) 0.09
History of spontaneous bleeding requiring hospitalization, n (%) 19/432 (4.4) 245/20 510 (1.2) <0.0001
Anemia,* n (%) 126/418 (30.1) 3723/20 082 (18.5) <0.0001
WBC (10×9/L), median (IQR) 6.7 (5.6–8.1) 6.9 (5.8–8.1) 0.10
Proton pump inhibitor use, n (%) 111/432 (25.7) 5378/20 510 (26.2) 0.81
CHF indicates congestive heart failure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MDRD, Modification of Diet in Renal Disease; TIMI, 
Thrombolysis in Myocardial Infarction; and WBC, white blood cell count.
*Anemia was defined as hemoglobin ≤13.5 g/dL for men and ≤12.0 g/dL for women.
Figure 1. TIMI major or minor bleeding by etiology (A) and site of 
spontaneous bleeding (B) in the overall safety population.
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bleeding requiring hospitalization, and anemia at baseline 
(Table 2). Supplemental Figure S3 shows cubic splines for 
hemoglobin and risk of TIMI major or minor bleeding in 
women (a) and men (b). Age, history of hypertension, and 
current smoking were also independent predictors of is-
chemic risk. However, anemia and a history of spontane-
ous bleeding requiring hospitalization were not.
Bleeding With Ticagrelor 60 mg Versus 
Placebo
Compared with placebo, ticagrelor 60 mg twice daily 
increased the risk of TIMI major or minor bleeding (HR, 
2.54; 95% CI, 1.93–3.35; P  <  0.001). The instantane-
ous hazard function for TIMI major or minor bleeding is 
shown in Figure S4. At 3 years, ticagrelor 60 mg twice 
daily increased TIMI major or minor bleeding by 2.0% 
(3.4% with ticagrelor compared with 1.4% with placebo). 
This excess was primarily in spontaneous bleeds (1.5%), 
traumatic (0.3%) or procedural (0.2%) (Figure 3a). The 
excess in spontaneous bleeds was primarily attributable 
to gastrointestinal bleeding (absolute risk increase, 1.1%; 
Figure 3b). The rate of gastrointestinal bleeding was less 
frequent in patients on ticagrelor 60 mg twice daily and 
a proton pump inhibitor (PPI), compared with patients 
not taking a PPI (0.4% versus 0.8%; HR, 0.47; 95% CI, 
0.27–0.82; P = 0.009).
There was no significant increase in ICH with ti-
cagrelor 60  mg compared with placebo (HR, 1.18; 
95% CI, 0.55–2.50; P = 0.67; Figure 3b). In addition, 
there was no significant increase in fatal bleeding or 
bleeding contributing to death with ticagrelor 60 mg 
relative to placebo (Figure 4). Results for ticagre-
lor 90 mg twice daily compared with placebo were 
similar and are reported in Figure S5a and S5b and 
Figure S6.
Efficacy and Safety of Ticagrelor 60 mg in 
Patients at High and Low Bleeding Risk
Based on the models of ischemic and bleeding risk, 
high bleeding risk was defined as either a history 
of spontaneous bleeding requiring hospitalization, 
anemia at baseline, or both (N=2714; 19% of the 
population), whereas low bleeding risk was defined 
as the absence of either characteristic (N=11 240; 
81% of the population). Table S1 shows baseline 
characteristics stratified by high versus low bleed-
ing risk in the overall population. When comparing 
the safety of ticagrelor 60  mg twice daily versus 
Figure 2. Incidence and cause of mortality among patients who experienced a TIMI major or minor bleeding (overall safety cohort).
TIMI indicates Thrombolysis in Myocardial Infarction.
Table 2. Independent Predictors of TIMI Major or Minor 
Bleeding in the Overall Population
Predictors HR (95% CI) P Value χ 2
Age (continuous, per 10-y increase) 1.47 (1.31–1.66) <0.0001 40.2
History of spontaneous bleeding 
requiring hospitalization
3.56 (2.24–5.64) <0.0001 29.1
Anemia at baseline 1.72 (1.39–2.13) <0.0001 24.6
Current smoker 1.59 (1.24–2.03) 0.0002 13.4
History of hypertension 1.43 (1.10–1.84) 0.007 7.3
c-index for variables listed 0.65 (95% CI, 0.62–0.68).
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placebo, the HR for TIMI major or minor bleeding 
was 2.93 (95% CI, 1.80–4.78) in patients at high 
bleeding risk, and 2.37 (95% CI, 1.70–3.32) in pa-
tients at low bleeding risk. There was a greater ab-
solute increase in the rate of TIMI major or minor 
bleeding with ticagrelor in the high-bleeding-risk 
group (increase of 4.4% at 3 years; 95% CI, 2.3%–
6.4%) compared with the increase with ticagrelor in 
patients in the low-bleeding-risk group (increase of 
1.5% at 3 years; 95% CI, 0.8%–2.1%) with a signifi-
cant interaction based on absolute differences (P 
value for absolute risk difference = 0.01; Figure 5). 
Table S2 shows the primary end point and TIMI 
major bleeding rates stratified by high versus low 
bleeding and ischemic risk.
In an exploratory analysis to evaluate the effi-
cacy of ticagrelor 60 mg twice daily compared with 
placebo on the basis of bleeding risk, ticagrelor 
60 mg reduced the risk of cardiovascular death, MI, 
or stroke by 20% in patients with low bleeding risk 
(HR, 0.80; 95% CI, 0.70–0.92; P = 0.0015; Figure 6). 
However, there was no apparent benefit of ticagrelor 
Figure 3. Etiologies (A) and sites (B) of TIMI major or minor bleeding, Ticagrelor 60 mg vs. placebo.
ARI indicates absolute risk increase; HR, hazard ratio, KM, Kaplan–Maier; NA, not applicable; and TIMI, Thrombolysis in Myocardial 
Infarction.
Figure 4. Bleeding and death, ticagrelor 60 mg vs placebo.
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in patients at high bleeding risk (HR, 0.98; 95% CI, 
0.77–1.26; P = 0.88, P interaction = 0.15). Results for 
the net clinical benefit showed a consistent pattern 
with ticagrelor 60 mg twice daily associated with fa-
vorable effects in the low-bleeding-risk patients (HR, 
0.82; 95% CI, 0.71– 0.94; P = 0.004) but no appar-
ent benefit in high bleeding risk (HR, 1.03; 95% CI, 
0.81–1.31). Finally, there was significant heterogeneity 
for mortality with ticagrelor based on low versus high 
bleeding risk with a reduction in low bleeding risk 
(HR, 0.79; 95% CI, 0.65–0.96) and no benefit in high 
bleeding risk (HR, 1.14; 95% CI, 0.86–1.50; P interac-
tion = 0.03; Figure 6, Table S3).
DISCUSSION
The current analysis provides three novel observations 
with regard to bleeding risk with ticagrelor in patients 
with prior MI. First, bleeding caused by ticagrelor in 
this population is most frequently spontaneous gas-
trointestinal bleeding in patients with occult sources, 
such as ulcer or malignancy. Second, there were 2 in-
dependent predictors of TIMI major or minor bleeding 
that were not independent predictors of ischemic risk, 
namely, prior hospitalization for bleeding and anemia. 
Finally, in an analysis of the efficacy of ticagrelor 60 
mg twice daily stratified by bleeding risk, those at low 
risk appeared to have greater benefit, including lower 
rates of mortality, while patients at high risk appeared 
to have no benefit.
The observation that more potent antithrombotic 
therapy increases spontaneous gastrointestinal bleed-
ing supports other recent trials evaluating bleed-
ing risk in stable secondary prevention populations.7 
Observations regarding gastrointestinal bleeding may 
be helpful in considering the risks and benefits of 
Figure 5. TIMI major or minor bleeding in ticagrelor 60 mg vs placebo group stratified by low 
(N=11 240) or high (N=2714) bleeding risk at baseline.
A sensitivity analysis of safety was performed based on baseline bleeding risk, defined as the presence 
or absence of either a history of spontaneous bleeding requiring hospitalization before the randomization 
or anemia (defined as hemoglobin ≤13.5 g/dL for men and ≤12.0 g/dL for women). ARI indicates absolute 
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therapy. In addition, they support strategies to reduce 
gastrointestinal bleeding such as PPI inhibitors, which 
have been shown to attenuate this risk.8,9 Finally, this 
analysis supports the identification of anemia as a key 
risk marker for future bleeding. This finding suggests 
that hemoglobin may be a simple and widely available 
biomarker that may identify patients at heightened risk 
of gastrointestinal bleeding with more intensive anti-
thrombotic therapy.
Predicting bleeding risk remains a challenge in clin-
ical practice. One issue is the recognition that many 
factors that predict bleeding, such as advanced age 
and renal dysfunction, also predict ischemic events 
and potential benefit of risk reduction therapies.10 
The Predicting Bleeding Complications in Patients 
Undergoing Stent Implantation and Subsequent Dual 
Antiplatelet Therapy score was derived to predict 
bleeding risk and in its validation showed a c-index of 
0.66.11 Findings from the current analysis both sup-
port and add novel information. First, prior bleeding 
and anemia in the current analysis demonstrates the 
predictive importance of these 2 factors. In contrast, 
white blood cell count was not predictive of bleeding 
in PEGASUS-TIMI 54, and the mechanism by which it 
would predict bleeding is unclear. Finally, in the current 
analysis, both age and renal dysfunction were associ-
ated with bleeding risk but also ischemic risk, and in 
the case of renal dysfunction, it has been shown pre-
viously to be associated with greater absolute benefit 
of ticagrelor.11 Importantly, the current analysis shows 
that in a stable post-MI population, the absence of the 
2 identified bleeding risk predictors did not reduce the 
ability to identify high bleeding risk, and in fact, their 
inclusion identified only 1 additional patient as high risk 
for bleeding (Table S4). Therefore, in a stable post-MI 
population, prior bleeding and anemia may be sufficient 
for bleeding risk prediction and may enable clinicians 
to consider bleeding and ischemic risk independently. 
This may be particularly helpful in groups such as the 
elderly in whom assessment of risk and benefit may be 
particularly challenging.
Although the findings of this analysis are explor-
atory, the greater efficacy of ticagrelor and formal 
interaction for all-cause mortality in low- versus high-
bleeding-risk patients helps to underscore the im-
portance of assessment of bleeding risk. Although 
there was no difference in fatal bleeding or the novel 
outcome of bleeding contributing to death with ti-
cagrelor, bleeding may lead to downstream conse-
quences such as procedures and discontinuation of 
antithrombotic therapies, which may increase the risk 
of mortality. In PEGASUS-TIMI 54, premature drug 
discontinuation was higher with ticagrelor than pla-
cebo and largely driven by bleeding and dyspnea.12 
In this context, the lower observed mortality in the 
low-bleeding-risk group suggests that the ischemic 
benefits outweigh the risks and downstream conse-
quences of bleeding.
There are several limitations to the current analy-
sis. The eligibility criteria for PEGASUS TIMI 54 led to 
a selected population that excluded some features as-
sociated with the risk of bleeding, such as low platelet 
Figure 6. Efficacy and safety of ticagrelor 60 mg vs placebo stratified by high (N=2714) or low (N=11 240) bleeding risk 
at baseline.
A sensitivity analysis of efficacy and safety was performed based on baseline bleeding risk, defined as the presence or absence 
of either a history of spontaneous bleeding requiring hospitalization before the randomization or anemia (defined as hemoglobin 
≤13.5 g/dL for men and ≤12.0 g/dL for women). ARI indicates absolute risk increase; ARR, absolute risk difference; CV, cardiovascular; 
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count, known bleeding diathesis, active malignancy, 
and prior stroke. In addition, use of PPI therapy was 
not randomized, and therefore we cannot conclude 
that PPI use would have mitigated gastrointestinal 
bleeding caused by ticagrelor; however, the COGENT 
(Clopidogrel and the Optimization of Gastrointestinal 
Events) trial did show significantly lower gastrointesti-
nal bleeding with PPI in patients receiving dual anti-
platelet therapy.8 It should also be noted that although 
apparent differences in outcomes between groups 
were observed, there was no formal heterogeneity by 
interaction testing for many outcomes, and this should 
be considered in interpreting the results. Finally, eval-
uations of efficacy and safety of ticagrelor by baseline 
bleeding risk were exploratory and should be viewed 
in this context.
CONCLUSIONS
In conclusion, in stable patients with prior MI treated 
with ticagrelor in addition to aspirin, TIMI major or 
minor bleeding is primarily spontaneous of gastrointes-
tinal origin and related to an underlying gastrointestinal 
disease. Ticagrelor 60 mg twice daily did not increase 
fatal bleeding or ICH. Anemia and prior hospitalization 
for bleeding independently predict bleeding risk but 
not ischemic risk in this population. In patients with 
neither of these bleeding predictors, the balance of ef-
ficacy and safety of long-term secondary prevention 
of MI with ticagrelor 60 mg twice daily appears to be 
favorable.
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Table S1. Baseline characteristics in the overall population stratified by high and low bleeding risk. 
Characteristic High Bleeding Risk 
N=4,054 
N (%) 




Age ≥ 75 986 (24.3) 2051 (12.1) <0.001 
Female 813 (20.1) 4190 (24.8) <0.001 
BMI, median (IQR) 27.1 
(24.2 – 30.4) 
28.1 
(25.4 – 31.2) 
<0.001 
Current Smoking 485 (12.0) 3019 (17.9) <0.001 
COPD 318 (7.9) 1150 (6.8) 0.0203 
History of Hypertension 3218 (79.4) 13020 (77.1) 0.0018 
Hypercholesterolemia 3061 (75.5) 13019 (77.1) 0.0309 
eGFR < 60 ml/min 1422 (35.3) 3366 (20.2) <0.001 
Diabetes Mellitus 1616 (39.9) 5119 (30.3) <0.001 
Peripheral Artery Disease 295 (7.3) 835 (4.9) <0.001 
Multivessel Coronary Disease 2333 (57.6) 10090 (59.8) 0.0109 
History of PCI 3295 (81.3) 14084 (83.4) 0.0012 






























Table S2. Primary endpoint and TIMI major bleeding rates stratified by high versus low bleeding and ischemic risk. 
 
 High Bleeding Risk 
events (KM%) 







 353 (11.36%) 
  
N= 14106 
 1055 (8.29%) 
  
TMB  N= 3511 
127 (5.25%) 








 22 (4.39%)  
  
N=2778 
 113 (4.58%) 
 
TMB N= 542 





*High ischemic risk defined as age ≥ 75, hypertension and current smoking, low ischemic risk is defined as the age < 75, no hypertension and no 
current smoking. 
(NOTE: A total of 20937 subjects out of safety population were included in this analysis. There were five subjects with missing Ischemic risk status.) 
(NOTE: 3 year KM estimates are reported) 































Table S3: Other outcomes of ticagrelor 60 mg vs. placebo stratified by high or low bleeding risk at baseline.   
 
Endpoint Ticagrelor 60 mg 
n (KM %) 
Placebo 
n (KM %) 
HR 95% CI P for interaction 
Myocardial 
infarction 
Lower bleeding risk 227 (4.39) 264 (5.09) 0.85 (0.72-1.02) 
0.71 
Higher bleeding risk 58 (5.14) 74 (5.94) 0.80 (0.56-1.12) 
Stroke     
Lower bleeding risk 67 (1.38) 100 (1.96) 0.66 (0.49-0.91) 
0.12 
Higher bleeding risk 24 (1.85) 22 (1.85) 1.12 (0.63-1.99) 
Coronary heart 
disease death 
Lower bleeding risk 61 (1.25) 97 (1.90) 0.63 (0-45-0.86) 
0.008 
Higher bleeding risk 45 (3.70) 35 (2.85) 1.30 (0.84-2.03) 
Non-CV Death 
Lower bleeding risk 74 (1.44) 73 (1.44) 1.01 (0.73-1.39) 
0.88 
Higher bleeding risk 39 (3.82) 38 (3.09) 1.06 (0.68-1.66) 
ICH or fatal 
bleeding 
Lower bleeding risk 22 (0.60) 22 (0.54) 1.09 (0.60-1.97) 
0.56 
Higher bleeding risk 11 (1.25) 8 (0.91) 1.51 (0.61-3.75) 
Myocardial infarction, 
Stroke, death, or TIMI 
major bleeding 
    
Lower bleeding risk 477 (11.36) 531 (11.51) 0.97 (0.86 – 1.10) 0.18 
Higher bleeding risk 181 (18.67) 170 (15.50) 1.15 (0.93 – 1.42)  
Myocardial infarction, 
Stroke, death, or TIMI 
major or minor bleeding 
    
Lower bleeding risk 513 (9.99) 546 (10.51) 0.94 (0.83 – 1.06) 0.0697 
Higher bleeding risk 201 (17.02) 177 (14.15) 1.16 (0.95 – 1.43)  
 



































PEGASUS TIMI 54 
Low bleeding risk* 
PEGASUS TIMI 54 
High bleeding risk* 
 N (%) 
ARI** 
3 yrs KM rate (%) 
N (%) 
ARI** 
3 yrs KM rate (%) 
Very low risk 16,337 (81.2) 1.8 3,775 (18.5) 3.6 
Low risk 6 (3.2) 0 182 (96.8) 7.8 
Moderate risk 1 (0) 0 50 (98) 21.7 
High risk 0 (0) 0 14 (100) 24 
* Based on anemia and history of spontaneous bleeding only 
**Absolute risk increase of TIMI major or minor bleeding, ticagrelor pooled vs. placebo 































Figure S1. Etiology and Sites of TIMI major or minor bleeding in the Ticagrelor 60 mg group (Safety cohort). 
 
 
































































































































































































Figure S5. Sites (a) and etiologies (b) of TIMI major or minor bleeding, Ticagrelor 90 mg vs. placebo. HR=Hazard Ratio, CI=Confidence 

















































































Figure S6. Bleeding and death, Ticagrelor 90 mg vs. placebo. HR=Hazard Ratio, CI=Confidence Interval, TIMI=Thrombolysis in Myocardial 
Infarction, KM=Kaplan Maier. 
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